FDA approves Abraxane for Pancreatic Cancer

The FDA has on 6 September 2013 expanded the approved uses of Abraxane (paclitaxel protein-bound particles for injectable suspension, ablumin-bound) from Celgene, to treat patients with late-stage (metastatic) Pancreatic Cancer.

The safety and effectiveness of Abraxane for Pancreatic Cancer were established in a clinical trial with 861 participants who were randomly assigned to receive Abraxane plus gemcitabine or gemcitabine alone. Participants treated with Abraxane plus gemcitabine lived, on average, 1.8 months longer than those treated with gemcitabine alone. Additionally, participants who received Abraxane plus gemcitabine experienced a delay in tumour growth (progression-free survival) that was, on average, 1.8 months later than the participants who only received gemcitabine.